Muhammad Zeinab A, Edrees Mastoura M, Faty Rasha A M, Gomha Sobhi M, Alterary Seham S, Mabkhot Yahia N
Department of Organic Chemistry, National Organization for Drug Control and Research (NODCAR), Giza 12311, Egypt.
Department of Chemistry, Faculty of Science, King Khalid University, Abha 61413, Saudi Arabia.
Molecules. 2017 Jul 20;22(7):1211. doi: 10.3390/molecules22071211.
A series of new morpholinylchalcones was prepared and then used as building blocks for constructing a series of 7-morpholino-2-thioxo-2,3-dihydropyrido[2,3-]pyrimidin-4(1)-ones via their reaction with 6-aminothiouracil. The latter thiones reacted with the appropriate hydrazonoyl chloride to give the corresponding pyrido[2,3-][1,2,4]triazolo[4,3-]pyrimidin-5(1)-ones. The assigned structures for all the newly synthesized compounds were confirmed on the basis of elemental analyses and spectral data and the mechanisms of their formation were also discussed. Most of the synthesized compounds were tested for in vitro activity against human lung cancer (A-549) and human hepatocellular carcinoma (HepG-2) cell lines compared with the employed standard antitumor drug (cisplatin) and the results revealed that compounds , and have promising activities against the A-549 cell line (IC values of 2.78 ± 0.86 μg/mL, 5.37 ± 0.95 μg/mL and 5.70 ± 0.91 μg/mL, respectively) while compound has promising activity against the HepG-2 cell lines (IC = 3.54 ± 1.11 μg/mL). Moreover, computational studies using MOE 2014.09 software supported the biological activity results.
制备了一系列新的吗啉基查尔酮,然后将其用作构建单元,通过与6-氨基硫脲嘧啶反应构建一系列7-吗啉基-2-硫代-2,3-二氢吡啶并[2,3 - ]嘧啶-4(1)-酮。后者的硫酮与适当的肼基酰氯反应,得到相应的吡啶并[2,3 - ][1,2,4]三唑并[4,3 - ]嘧啶-5(1)-酮。基于元素分析和光谱数据确认了所有新合成化合物的指定结构,并讨论了它们的形成机制。与使用的标准抗肿瘤药物(顺铂)相比,测试了大多数合成化合物对人肺癌(A-549)和人肝癌(HepG-2)细胞系的体外活性,结果表明化合物、和对A-549细胞系具有有前景的活性(IC值分别为2.78±0.86μg/mL、5.37±0.95μg/mL和5.70±0.91μg/mL),而化合物对HepG-2细胞系具有有前景的活性(IC = 3.54±1.11μg/mL)。此外,使用MOE 2014.09软件的计算研究支持了生物活性结果。